COVID Vaccines Significantly Increase Risk of Myocarditis After Second Dose, Especially in Young Males: Study

By Enrico Trigoso | July 8, 2022

Another peer-reviewed study based on passive surveillance from Ontario, Canada, found that the rate of myocarditis was greater in younger males than females, and also greater after the second dose than the first dose of an mRNA vaccine.

On June 17, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for Moderna and Pfizer vaccines for children as young as 6 months old.

On June 24, the CDC (Centers for Disease Control and Prevention) started recommending COVID vaccines to everyone aged 6 months or older and COVID-19 boosters for “everyone ages 5 years and older.”

Dr. Sanjay Verma, a cardiologist from California, told The Epoch Times that the agency is doing this “regardless of risk stratification or prior infection with SARS-CoV2. Using data mostly from VAERS, supplemented with VSD (Vaccine Safety Datalink) data, CDC continues to assert that the COVID-19 vaccines are ‘safe and effective.’”

Previous studies have shown rapidly decreasing vaccine efficacy (VE) in children as well as adolescents during the first few months after completing vaccination.

“The decreasing VE then begs the question if the benefits outweigh the risks in healthy children and young adults given the known increased, albeit rare, risk of myocarditis,” Verma said.

The study had the goal of assessing the association between specific vaccine products to differences in rates of myocarditis or pericarditis; Further estimating the rates based on age, sex, dose number, and interval between the shots.

The study found 97.3 cases of myocarditis per million doses of BNT162b2 (Pfizer) for 12–17-year-old males and 299.5 per million doses of mRNA-1273 (Moderna) for 18–24-year-old males.

The population-based cohort study was published on June 24 and conducted from December 2020 to September 2021 and used data from Ontario’s COVID-19 vaccine registry and passive vaccine-safety surveillance system.

“As the authors also mention in the discussion, this is substantially higher than the VAERS data reported by CDC (38.5 per million for mRNA-1273 doses in males and 69.1 per million BNT162b2 doses for males 16-17 years old,)” Verma said.

“Furthermore, the authors continue, using data from four claims databases, FDA reported a rate of 283 cases of myocarditis per million of mRNA-1271 doses for males 18-25 years old. This is closer to the rate found in this study (299.5 per million). Vaccine Safety Data (VSD) data, the authors note, found the adjusted rate of myocarditis or pericarditis to be 2.72 times greater for dose 2 of mRNA-1273 than dose 2 of BNT162b2.”

Child Vaccination

Dr. James Thorp, a maternal-fetal medicine expert, believes that children should not take the vaccine.

Thorp told The Epoch Times that: “There is absolutely no basis for giving lethal experimental injections to babies and children. There is absolutely zero epidemiological or clinical data to support this. There is no ’emergency use authorization’ when there is no emergency.”

“The COVID-19 injections were never necessary. The scientific verdict is in and 95 percent of COVID-19 deaths are prevented by early therapies with nutraceuticals, vitamins, and repurposed medications,” Thorp said.

The CDC’s Interim Clinical Considerations said in regards to issues of interchangeability of shots from different manufacturers (when one takes a first dose from Pfizer and then a second form Moderna), that “in exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, any age-appropriate mRNA COVID-19 vaccine product may be administered.”

And as for the vaccine boosters, the CDC’s recommendations are, “Any age-appropriate mRNA vaccine can be used for the booster dose(s): it can be the same mRNA vaccine as the primary series (homologous booster dose) or a different mRNA vaccine (heterologous booster dose).”

“However,” Verma said: “In the Supplementary Online Content of this study, the authors report that when vaccines are mixed (i.e., dose 1 and dose 2 are different manufacturers), the rate of myocarditis can be as high as 799 per million if mRNA-1273 is the second dose after initial BNT162b2 dose. The risk with heterologous dosing thus is 2.67 times higher than homologous dosing.”

New York Protests

On Wednesday, about 20 police barricaded a vaccine center in New York due to demonstrators protesting against the COVID vaccination of babies and children.

On July 2, protestors were recorded outside a vaccination center in Times Square begging parents taking their children into the center not to vaccinate them and asking them to do more research before doing a potentially irreversible medical procedure.



One thought on “COVID Vaccines Significantly Increase Risk of Myocarditis After Second Dose, Especially in Young Males: Study

Leave a Reply

Your email address will not be published. Required fields are marked *